Karine Clauwaert joined the 272bio team in 2021 to drive business development. Karine qualified as a Pharmacist in 1992 and went on to gain a PhD in pharmaceutical sciences at Ghent University in the laboratory of toxicology in 1998. Between 1997 and 2003 Karine was a postdoc at Ghent University and also worked at Micromass Europe as a product specialist in the Benelux.
Since 2003 Karine has been a dedicated business developer in heart and soul.
Between 2003 and 2015 she was the business development manager at VIB where she was responsible for proactive marketing of VIB technologies and for negotiating, drafting and concluding agreements between VIB and industry. Within VIB, Karine developed a strong knowledge about VHH molecules as VIB (together with VUB) is the cradle of the VHH technology. From 2015 until 2019 Karine was director business development at Eurofins CDMO. At Eurofins she scouted for new users Eurofins its CDMO services. This job entailed also the provision of quotations, negotiation of contracts and following up the projects with the customers. Since 2019 Karine has been an independent consultant helping companies with their business development activities and CMC related activities.
Our Management Team leverages their deep industry experience, data-driven insights and strategic innovation to empower our team of advocates who deliver novel healthcare solutions that help customers succeed in an increasingly challenging business climate.